Study shows:

The effectiveness of the Pfizer Inc (PFE.N)/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose, according to data published on Monday that US health agencies considered when deciding on the need for booster shots.

Iran PressAmerica: The data, which was published in the Lancet medical journal, had been previously released in August ahead of peer review.

The analysis showed that the vaccine's effectiveness in preventing hospitalization and death remained high at 90% for at least six months, even against the highly contagious Delta variant of the coronavirus, Reuters reported.

The data suggests that the drop is due to waning efficacy, rather than more contagious variants, researchers said.

Related news:

Pfizer vaccine is not reliable: MP

Researchers from Pfizer and Kaiser Permanente studied electronic health records of roughly 3.4 million people who were members of Kaiser Permanente Southern California between December 2020 - when the vaccine first became available - and August of 2021.

"Our variant-specific analysis clearly shows that the (Pfizer/BioNTech) vaccine is effective against all current variants of concern, including Delta," said Luis Jodar, senior vice president and chief medical officer at Pfizer vaccines.

A potential limitation of the study was a lack of data on adherence to masking guidelines and occupations in the study population, which could have affected the frequency of testing and the likelihood of exposure to the virus.

Vaccine effectiveness against the Delta variant was 93% after the first month, declining to 53% after four months. Against other coronavirus variants, efficacy declined to 67% from 97%.

The US Food and Drug Administration has authorized the use of a booster dose of the Pfizer/BioNTech vaccine for older adults and some Americans at high risk of getting infected. Scientists have called for more data on whether boosters should be recommended for all.

207

Read more:

Pfizer COVID-19 shot for kids age 5-11 could be authorized in October: Sources

 

Pfizer-BioNTech reduced the number of vaccines to EU countries